Profile
| Metric | Value |
|---|---|
| Full Name | Beam Therapeutics Inc. |
| Ticker | NASDAQ: BEAM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | beamtx.com |
| Employees | 393 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $31.56 | |
| Price, 1D Change | -7.88% | |
| Market Cap | $3B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.64 | |
| Revenue | $64M | |
| Revenue, 1Y Change | -83.18% | |
| EPS | -$4.58 | |
| EPS, 1Y Change | -166.46% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.58 | |
| EPS Estimate | -$4.39 | |
| EPS Est. Change | +4.09% | |
| Revenue | $63.52M | |
| Revenue Estimate | $39.42M | |
| Revenue Est. Change | -37.94% | |
| Current Price | $31.56 | |
| Price Target | - | $42.00 |
| Price Tgt. Change | - | +33.08% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$4.42 | -$1.72 | +61.14% | |
| -$4.68 | -$4.58 | +2.23% | |
| -$4.39 | N/A | +4.09% | |
| -$4.58 | N/A | -0.12% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $79.20M | $377.71M | +376.91% | |
| $51.42M | $63.52M | +23.53% | |
| $39.42M | N/A | -37.94% | |
| $46.74M | N/A | -26.41% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +20.05% | |
| Price, 3Y | -28.90% | |
| Market Cap, 1Y | +45.66% | |
| Market Cap, 3Y | +1.22% | |
| Revenue, 1Y | -83.18% | |
| Revenue, 3Y | +22.52% | |
| EPS, 1Y | -166.46% | |
| EPS, 3Y | +20.69% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $31.56 | |
| SMA 200 | $21.82 | |
| SMA 200 vs Price | -30.86% | |
| SMA 50 | $26.98 | |
| SMA 50 vs Price | -14.52% | |
| Beta | 1.64 | |
| ATR | $2.41 | |
| 14-Day RSI | 55.53 | |
| 10-Day Volatility | 144.88% | |
| 1-Year Volatility | 79.25% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $63.52M | |
| EPS | -$4.58 | |
| Gross Profit | $41.59M | |
| Gross Margin | 65.48% | |
| Operating Profit | -$415.57M | |
| Operating Margin | -654.25% | |
| Net Income | -$376.74M | |
| Net Margin | -593.13% | |
| EBITDA | -$393.64M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.22 | |
| Current Ratio | 4.82 | |
| Quick Ratio | 4.82 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | 2.77 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 57.50 | |
| PB Ratio | 3.32 | |
| EV/EBITDA | -5.13 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $733.55M | |
| Cash & Equivalents | $281.97M | |
| Total Assets | $1.10B | |
| Current Assets | $878.15M | |
| Total Liabilities | $370.28M | |
| Current Liabilities | $182.07M | |
| Total Debt | $161.43M | |
| Short Term Debt | $13.47M | |
| Accounts Payable | $3.87M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $440.26M | |
| Operating Expenses | $457.16M | |
| Cost Of Goods Sold | $21.93M | |
| SG&A | $0.00 | |
| D&A | $21.93M | |
| Interest Expense | $0.00 | |
| Income Tax | $39.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$347.25M | |
| CFI | $185.01M | |
| CFF | $7.74M | |
| Capex | $8.95M | |
| Free Cash Flow | -$356.19M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| UBS | ||
| Evercore ISI Group | ||
| HC Wainwright & Co. | → | |
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| Barclays | → | |
| Wells Fargo | → | |
| Guggenheim | → | |
| Barclays | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with BEAM
FAQ
What is the ticker symbol for Beam Therapeutics Inc.?
The ticker symbol for Beam Therapeutics Inc. is NASDAQ:BEAM
Does Beam Therapeutics Inc. pay dividends?
No, Beam Therapeutics Inc. does not pay dividends
What sector is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. is in the Healthcare sector
What industry is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. is in the Biotechnology industry
What country is Beam Therapeutics Inc. based in?
Beam Therapeutics Inc. is headquartered in United States
When did Beam Therapeutics Inc. go public?
Beam Therapeutics Inc. initial public offering (IPO) was on February 6, 2020
Is Beam Therapeutics Inc. in the S&P 500?
No, Beam Therapeutics Inc. is not included in the S&P 500 index
Is Beam Therapeutics Inc. in the NASDAQ 100?
No, Beam Therapeutics Inc. is not included in the NASDAQ 100 index
Is Beam Therapeutics Inc. in the Dow Jones?
No, Beam Therapeutics Inc. is not included in the Dow Jones index
When was Beam Therapeutics Inc. last earnings report?
Beam Therapeutics Inc.'s most recent earnings report was on November 4, 2025
When does Beam Therapeutics Inc. report earnings?
The next expected earnings date for Beam Therapeutics Inc. is February 24, 2026
Data Sources & References
- BEAM Official Website beamtx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1745999/000119312525263542/0001193125-25-263542-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1745999/000095017025026076/0000950170-25-026076-index.htm
- BEAM Profile on Yahoo Finance finance.yahoo.com/quote/BEAM
- BEAM Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/beam